Secukinumab Biosimilar, Anti-human IL-17A Antibody | Catalog C034P

Secukinumab Biosimilar, Human IL17A Monoclonal Antibody. The research grade Secukinumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C034P
Product Name	Secukinumab Biosimilar, Human IL17A Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	IL-17A, interleukin 17A, IL-17, interleukin 17, Secukinumab Research Grade, Secukinumab RUO
Summary	Recombinant fully human IgG1 monoclonal antibody.
Source/Host	Produced in mammalian cells.
Specificity	Specifically binds to the human IL17A.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by secukinumab.
Formulation	0.2 µM filtered solution, pH 5.8, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells.

IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.